Unaudited Quarterly Financial Data (Parenthetical) (Detail) (Rising Pharmaceuticals Inc. [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended
Dec. 31, 2010	Jun. 30, 2011
Rising Pharmaceuticals Inc. [Member]
Quarterly Financial Information [Line Items]
Business acquisition, reversal of tax charge related to repatriation of earnings from certain foreign subsidiaries	$ 2,600	$ 2,600
Business acquisition, transaction costs	$ 1,060

Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant